Here are the 10-K annual reports from Genvor Inc (GNVR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GNVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNVR filings page.
Genvor Incorporated is a pre-revenue agricultural biotechnology company developing AI-accelerated peptide technologies to protect crops and enhance yields through seed traits and biological sprays. Its BioCypher Algorithm and peptide library underpin patented antimicrobial and nutritionally enhanced peptides, supported by USDA cooperative research and a 2024 Bayer Golden Ticket providing lab space and mentorship.
For the year ended September 30, 2025, Genvor generated no revenue and recorded a net loss of $5,589,041, compared with a $2,884,958 loss in 2024, driven mainly by $5,497,998 of compensation and related benefits. Other income of $820,810 reflected gains on settling and derecognizing debt. At September 30, 2025, cash was $37,231 with a working capital deficit of $1,312,382, and auditors highlighted substantial doubt about the company’s ability to continue as a going concern.
The company’s common stock trades as a penny stock on the OTC Link ATS under “GNVR,” with 34,511,855 shares outstanding as of December 8, 2025. During the 2025 fiscal year it raised modest equity capital through small private share sales and issued stock for services and compensation while continuing to rely on partnerships and licensing plans to advance its pipeline.
Genvor Inc. (GNVR) filed a Form 10-K/A correcting a typographical error in its independent auditor's signature date and restating select disclosure items from its 2023 Annual Report. The filing discloses that for the year ended September 30, 2023 the Company recognized a net loss of $1,707,481, had no revenues, and used $871,734 in operating cash, and that these conditions raise substantial doubt about the Companys ability to continue as a going concern. The filing details multiple debt instruments, including a note maturing March 13, 2024 with 10% interest convertible into 134,000 common shares, conversions of $989,000 principal and $146,946 interest into 2,316,147 common shares, and other conversions and warrant issuances. It reports extensive share issuances and transfers across Series A and B preferred and common stock, related-party transactions and settlement terms, net operating loss carryforwards of $2,497,000 and $2,133,000 (available through 2043), deferred tax asset balances, and various contingent liabilities, fees, and subsequent small equity issuances. The filing also references a merger with Old Genvor and settlement payments tied to cancellation of preferred shares.